Idorsia Ltd.

Idorsia Ltd (IDRSF) Q2 2026 Earnings Call Transcript

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension

Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026

Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year

Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript

Idorsia announces the nomination of three candidates for election to the Board of Directors

Idorsia announces management change

Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink

Idorsia Ltd (IDRSF) Q4 2025 Earnings Call Transcript

Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling – further sales growth ahead with multiple pipeline catalysts in 2026

Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call

Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium

Global expansion of Idorsia's QUVIVIQ continues with EMS partnership for Latin America

Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Idorsia to present at J.P. Morgan 2026 Healthcare Conference

Nature Communications reports promising effect of Idorsia's lucerastat on kidney function in Fabry disease